secwatch.observer — SEC 8-K summary
======================================

Issuer:     Edwards Lifesciences Corp (EW)
CIK:        0001099800
Form:       8-K
Filed at:   2024-10-24T23:59:59+00:00
Accession:  0001099800-24-000084
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Edwards Q3 sales up 9% to $1.33B; TAVR +6%, TMTT +73%; adjusted EPS $0.67 beats guidance
--------------------------------------------------------------------------------

- Q3 sales from continuing ops $1.33B (+9% as-reported, +10% constant currency); adjusted EPS $0.67 ahead of July guidance.
- TAVR sales $1.0B (+6% reported, +7% constant currency); TMTT sales $91M (+73%) driven by PASCAL and EVOQUE launches.
- GAAP EPS $5.13 includes one-time gain from sale of Critical Care unit; adjusted gross margin 80.7% vs 79.9% last year.
- Repurchased $1.0B of stock in Q3; remaining authorization $1.4B; cash $3.5B, debt $600M.
- Reiterated FY2024 total sales growth 8-10%; Q4 guidance: sales $1.33-1.39B, EPS $0.53-0.57.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1099800/000109980024000084/0001099800-24-000084-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1099800/000109980024000084/ew-20241024.htm
  HTML page:      https://secwatch.observer/filing/0001099800-24-000084

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer